Inspira Technologies has deployed its FDA-cleared INSPIRA™ ART100 system at a leading U.S. academic medical center in New York State. This move expands the company’s presence in Tier-1 U.S. hospitals and aims to define clinical protocols for broader adoption. Mike Hershkovitz, Global VP Sales, sees this as part of the company’s U.S. commercial strategy. The INSPIRA ART100 system is designed for cardiopulmonary bypass in the U.S. and ECMO procedures elsewhere. It serves as a foundation for the INSPIRA ART500 system and HYLA blood sensor platform. The company is focused on converting evaluations into a sustainable commercial pipeline and expanding across key U.S. markets.

Read more at GlobeNewswire: Inspira Expands U.S. Commercial Footprint: Deploys ART100